GLP-1 Agonist Therapy Center

Prepared by Margarita Stanosyan, Doctor of Pharmacy Candidiate, LECOM College of Pharmacy, this terrific collection of Homerun Slides will give you everything you need to know about GLP-1 Analogs and how they help promote and work with the lifestyle changes your patients need to be addressing. Link to download (.ppt format): GLP-1 …

Cierra Harden PharmD Candidate 2013 LECOM School of Pharmacy, Bradenton Obesity is a major risk factor for the development of diabetes as well as predisposing individuals to hypertension and dyslipidemia. In the United States, 54.8% of persons with diabetes are obese, and 85.2% are overweight or obese1. All of these …

Alan Mathis PharmD Candidate 2013 University of Florida GLP-1 analogs not only improve plasma glucose levels and reduce HbA1c, but also improve metabolic effects such as reduction in BMI, waist circumference, and improve cardiovascular health. Diabetic patients, especially with type 2 diabetes, tend to have poor diets and sedentary lifestyle …

Andre McMahon, PharmD Candidate UF College of Pharmacy Achieving glycemic control is a critical goal in the management of patients with type 2 diabetes mellitus (DM). Hyperglycemia contributes to the progression of DM by adversely affecting both the body’s sensitivity to insulin and beta-cell function. Type 2 DM results from …

Alan Mathis, PharmD Candidate 2013, University of Florida College of Pharmacy The pathophysiology of type-2 diabetes is characterized by insulin resistance and beta-cell dysfunction. In addition, the presence of high levels of glucagon in the blood also seems to play an important role in the disease. Glucagon-like peptide-1 (GLP-1) is a …

In this week’s Homerun Slides, we have Part 2 of our special slide collection of GLP-1 Agonists and Cardiovascular Health. Topics covered include: Cardiac Actions of GLP-1, and Effects of GLP-1 Agonists on Inflammatory Markers…. Link to download (.ppt format): GLP-1 Agonists and Cardiovascular Health, Part 2 of 2 Other sets …

This set of Homerun Slides put together by Diabetes In Control staff is specifically geared towards the cardiovascular benefits of incretins.  Link to download (.ppt format): GLP-1 Agonists and Cardiovascular Health, Part 1 of 2 Other sets in this series: GLP-1 Agonists and Cardiovascular Health, Part 2 of 2 See more GLP-1 Agonist …

What are the results after adding a GLP-1 receptor agonist to the treatment of type 2 patients after 30+ weeks of treatment?… During recent years, two strategies of incretin-based therapy [glucagon-like peptide-1 (GLP-1) receptor agonism and dipeptidyl peptidase-4 (DPP-4) inhibition] have entered the market for pharmacological management of type 2 …

Tina Burge, Doctor of Pharmacy Candidate, FAMU College of Pharmacy Reviewed by Dave Joffe, BSPharm, CDE It’s well-known that patients with diabetes have an increased risk of cardiovascular disease when compared to patients without diabetes. Diabetes type 2 has a high prevalence in the obese (BMI ³ 25kg/m2) and overweight …

The top three drugs for the reduction of A1c levels are biphasic insulin, glucagon-like peptide 1 (GLP-1) analogs, and….  The top 3 drugs for the reduction of A1c levels are biphasic insulin, glucagon-like peptide 1 (GLP-1) analogs, and basal insulin. Although most oral antidiabetic drugs had a similar effect on …